203 related articles for article (PubMed ID: 30885361)
21. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling.
Shui JW; Steinberg MW; Kronenberg M
J Leukoc Biol; 2011 Apr; 89(4):517-23. PubMed ID: 21106644
[TBL] [Abstract][Full Text] [Related]
22. Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160.
Shrestha R; Garrett-Thomson SC; Liu W; Almo SC; Fiser A
Structure; 2020 Nov; 28(11):1197-1205.e2. PubMed ID: 32795404
[TBL] [Abstract][Full Text] [Related]
23. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
[TBL] [Abstract][Full Text] [Related]
24. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C; Speiser DE; Derré L; Olive D
Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
[TBL] [Abstract][Full Text] [Related]
25. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
Cheung TC
Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
[TBL] [Abstract][Full Text] [Related]
26. CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.
Flynn R; Hutchinson T; Murphy KM; Ware CF; Croft M; Salek-Ardakani S
PLoS One; 2013; 8(10):e77991. PubMed ID: 24205056
[TBL] [Abstract][Full Text] [Related]
27. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
[TBL] [Abstract][Full Text] [Related]
28. Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.
Pasero C; Truneh A; Olive D
Curr Mol Med; 2009 Sep; 9(7):911-27. PubMed ID: 19860669
[TBL] [Abstract][Full Text] [Related]
29. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic Function of Herpesvirus Entry Mediator in Experimental Autoimmune Uveitis by Induction of Th1- and Th17-Type T Cell Responses.
Sakoda Y; Nagai T; Murata S; Mizuno Y; Kurosawa H; Shoda H; Morishige N; Yanai R; Sonoda KH; Tamada K
J Immunol; 2016 Apr; 196(7):2947-54. PubMed ID: 26912321
[TBL] [Abstract][Full Text] [Related]
31. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
[TBL] [Abstract][Full Text] [Related]
32. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
Vendel AC; Jaroszewski L; Linnik MD; Godzik A
Clin Pharmacol Ther; 2024 Jul; 116(1):247-256. PubMed ID: 38676311
[TBL] [Abstract][Full Text] [Related]
33. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
[TBL] [Abstract][Full Text] [Related]
34. Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction.
del Rio ML; Jones ND; Buhler L; Norris P; Shintani Y; Ware CF; Rodriguez-Barbosa JI
J Immunol; 2012 May; 188(10):4885-96. PubMed ID: 22490863
[TBL] [Abstract][Full Text] [Related]
35. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT.
Rodriguez-Barbosa JI; Schneider P; Weigert A; Lee KM; Kim TJ; Perez-Simon JA; Del Rio ML
Cell Mol Immunol; 2019 Jul; 16(7):679-682. PubMed ID: 31160757
[No Abstract] [Full Text] [Related]
36. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.
De Trez C; Schneider K; Potter K; Droin N; Fulton J; Norris PS; Ha SW; Fu YX; Murphy T; Murphy KM; Pfeffer K; Benedict CA; Ware CF
J Immunol; 2008 Jan; 180(1):238-48. PubMed ID: 18097025
[TBL] [Abstract][Full Text] [Related]
37. Role of BTLA/HVEM network in development of gastric cancer.
Azarafza M; Tehrani M; Valadan R; Maleki I; Mohammad Mehdi Ghaffari-Hamedani S; Ghanadan A; Alizadeh-Navaei R; Ajami A
Hum Immunol; 2022; 83(8-9):637-644. PubMed ID: 35914980
[TBL] [Abstract][Full Text] [Related]
38. Regulatory role of BTLA and HVEM checkpoint inhibitors in T cell activation in a perciform fish Larimichthys crocea.
Jin CY; Su N; Hu CB; Shao T; Ji JF; Qin LL; Fan DD; Lin AF; Xiang LX; Shao JZ
Dev Comp Immunol; 2022 Mar; 128():104312. PubMed ID: 34767880
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus.
Zhang M; Howard K; Winters A; Steavenson S; Anderson S; Smelt S; Doellgast G; Sheelo C; Stevens J; Kim H; Hamburger A; Sein A; Caughey DJ; Lee F; Hsu H; Siu G; Byrne FR
Clin Exp Immunol; 2011 Jan; 163(1):77-87. PubMed ID: 21078085
[TBL] [Abstract][Full Text] [Related]
40. The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients.
Wojciechowicz K; Kuncewicz K; Rutkowski J; Jassem J; Wardowska A; Spodzieja M
Front Immunol; 2024; 15():1362152. PubMed ID: 38835768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
